The relationship between visceral adipose index and resistant hypertension in people living with diabetes

References

• Lawes CM, Vander Hoorn S, Rodgers A. Global burden of blood-pressure-related disease, 2001. Lancet. 2008;371(9623):1513–1518.
   PubMed Web of Science ®Google Scholar
• Danaei G, Ding EL, Mozaffarian D, et al. The preventable causes of death in the United States: comparative risk assessment of dietary, lifestyle, and metabolic risk factors. PLOS Med. 2009;6(4):e1000058. DOI:10.1371/journal.pmed.1000058
   PubMed Web of Science ®Google Scholar
• Chiu N, Lauffenburger JC, Franklin JM, et al. Prevalence, predictors, and outcomes of both true- and pseudo-resistant hypertension in the action to control cardiovascular risk in diabetes trial: a cohort study. Hypertens Res. 2021;44(11):1471–1482. DOI:10.1038/s41440-021-00739-6
   PubMed Web of Science ®Google Scholar
• 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. (2018). Hypertension (Dallas, Tex: 1979). 2018;72(3):e33 doi:10.1161/HYP.0000000000000080.
   PubMed Web of Science ®Google Scholar
• Daugherty SL, Powers JD, Magid DJ, et al. Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation. 2012;125(13):1635–1642. DOI:10.1161/CIRCULATIONAHA.111.068064
   PubMed Web of Science ®Google Scholar
• Cuspidi C, Macca G, Sampieri L, et al. High prevalence of cardiac and extracardiac target organ damage in refractory hypertension. J Hypertens. 2001;19(11):2063–2070. DOI:10.1097/00004872-200111000-00018
   PubMed Web of Science ®Google Scholar
• Gupta AK, Nasothimiou EG, Chang CL, et al. Baseline predictors of resistant hypertension in the Anglo-Scandinavian Cardiac Outcome Trial (ASCOT): a risk score to identify those at high-risk. J Hypertens. 2011;29(10):2004–2013. DOI:10.1097/HJH.0b013e32834a8a42
   PubMed Web of Science ®Google Scholar
• Brant LCC, Passaglia LG, Pinto-Filho MM, et al. The burden of resistant hypertension across the world. Curr Hypertens Rep. 2022;24(3):55–66. DOI:10.1007/s11906-022-01173-w
   PubMed Web of Science ®Google Scholar
• Wan H, Wang Y, Xiang Q, et al. Associations between abdominal obesity indices and diabetic complications: Chinese visceral adiposity index and neck circumference. Cardiovasc Diabetol. 2020;19(1):118. DOI:10.1186/s12933-020-01095-4
   PubMed Web of Science ®Google Scholar
• Neeland IJ, Poirier P, Després JP. Cardiovascular and metabolic heterogeneity of obesity: clinical challenges and implications for management. Circulation. 2018;137(13):1391–1406.
   PubMed Web of Science ®Google Scholar
• Ding Y, Gu D, Zhang Y, et al. Significantly increased visceral adiposity index in prehypertension. PLoS ONE. 2015;10(4):e0123414. DOI:10.1371/journal.pone.0123414
   PubMed Web of Science ®Google Scholar
• Zhang M, Zheng L, Li P, et al. 4-year trajectory of visceral adiposity index in the development of type 2 diabetes: a prospective cohort study. Ann Nutr Metab. 2016;69(2):142–149. DOI:10.1159/000450657
   PubMed Web of Science ®Google Scholar
• Amato MC, Giordano C, Galia M, et al. Visceral Adiposity Index: a reliable indicator of visceral fat function associated with cardiometabolic risk. Diabetes Care. 2010;33(4):920–922. DOI:10.2337/dc09-1825
   PubMed Web of Science ®Google Scholar
• Brambilla G, Bombelli M, Seravalle G, et al. Prevalence and clinical characteristics of patients with true resistant hypertension in central and Eastern Europe: data from the BP-CARE study. J Hypertens. 2013;31(10):2018–2024. DOI:10.1097/HJH.0b013e328363823f
   PubMed Web of Science ®Google Scholar
• Smith SM, Gong Y, Handberg E, et al. Predictors and outcomes of resistant hypertension among patients with coronary artery disease and hypertension. J Hypertens. 2014;32(3):635–643. DOI:10.1097/HJH.0000000000000051
   PubMed Web of Science ®Google Scholar
• Sarganas G, Neuhauser HK. Untreated, uncontrolled, and apparent resistant hypertension: results of the German health examination survey 2008-2011. J Clin Hypertens (Greenwich). 2016;18(11):1146–1154.
   PubMed Web of Science ®Google Scholar
• Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021–3104. DOI:10.1093/eurheartj/ehy339
   PubMed Web of Science ®Google Scholar
• Lamirault G, Artifoni M, Daniel M, et al. Resistant hypertension: novel insights. Curr Hypertens Rev. 2020;16(1):61–72. DOI:10.2174/1573402115666191011111402
   PubMed Web of Science ®Google Scholar
• Pierdomenico SD, LAPENNA D, BUCCI A, et al. Cardiovascular outcome in treated hypertensive patients with responder, masked, false resistant, and true resistant hypertension. Am J Hypertens. 2005;18(11):1422–1428. DOI:10.1016/j.amjhyper.2005.05.014
   PubMed Web of Science ®Google Scholar
• Tsioufis C, Kasiakogias A, Kordalis A, et al. Dynamic resistant hypertension patterns as predictors of cardiovascular morbidity: a 4-year prospective study. J Hypertens. 2014;32(2):415–422. DOI:10.1097/HJH.0000000000000023
   PubMed Web of Science ®Google Scholar
• Gupta R, Sharma KK, Soni S, et al. Resistant hypertension in clinical practice in India: Jaipur Heart Watch. J Assoc Physicians India. 2019;67(12):14–17.
   PubMedGoogle Scholar
• Shimabukuro M, Kozuka C, Taira S-I, et al. Ectopic fat deposition and global cardiometabolic risk: new paradigm in cardiovascular medicine. J Med Invest. 2013;60(1–2):1–14. DOI:10.2152/jmi.60.1
   PubMedGoogle Scholar
• Fiorentino TV. Visceral adiposity index (VAI), a powerful predictor of incident hypertension in prehypertensives. Intern Emerg Med. 2018;13(4):471–473.
   PubMedGoogle Scholar
• Wei J, et al. Comparisons of visceral adiposity index, body shape index, body mass index and waist circumference and their associations with diabetes mellitus in adults. Nutrients. 2019;11(7):1580. DOI:10.3390/nu11071580
   PubMed Web of Science ®Google Scholar
• Oh JY, Sung YA, Lee HJ. The visceral adiposity index as a predictor of insulin resistance in young women with polycystic ovary syndrome. Obesity (Silver Spring). 2013;21(8):1690–1694.
   PubMed Web of Science ®Google Scholar
• de Mutsert R, Gast K, Widya R, et al. Associations oF abdominal subcutaneous and visceral fat with insulin resistance and secretion differ between men and women: the Netherlands epidemiology of obesity study. Metab Syndr Relat Disord. 2018;16(1):54–63. DOI:10.1089/met.2017.0128
   PubMed Web of Science ®Google Scholar
• Wang F, Han L, Hu D. Fasting insulin, insulin resistance and risk of hypertension in the general population: a meta-analysis. Clin Chim Acta. 2017;464:57–63.
   PubMed Web of Science ®Google Scholar
• Androulakis ES, Tousoulis D, Papageorgiou N, et al. Essential hypertension: is there a role for inflammatory mechanisms? Cardiol Rev. 2009;17(5):216–221. DOI:10.1097/CRD.0b013e3181b18e03
   PubMed Web of Science ®Google Scholar
• Bilgin S, Aktas G, Zahid Kocak M, et al. Association between novel inflammatory markers derived from hemogram indices and metabolic parameters in type 2 diabetic men. Aging Male. 2020;23(5):923–927. DOI:10.1080/13685538.2019.1632283
   PubMed Web of Science ®Google Scholar
• Aktas G, Khalid A, Kurtkulagi O, et al. Poorly controlled hypertension is associated with elevated serum uric acid to HDL-cholesterol ratio: a cross-sectional cohort study. Postgrad Med. 2022;134(3):297–302. DOI:10.1080/00325481.2022.2039007
   PubMed Web of Science ®Google Scholar
• Welty FK. How do elevated triglycerides and low HDL-cholesterol affect inflammation and atherothrombosis? Curr Cardiol Rep. 2013;15(9):400.
   PubMed Web of Science ®Google Scholar
• Tylutka A, Morawin B, Walas Ł, et al. Assessment of metabolic syndrome predictors in relation to inflammation and visceral fat tissue in older adults. Sci Rep. 2023;13(1):89. DOI:10.1038/s41598-022-27269-6
   PubMed Web of Science ®Google Scholar
• McMaster WG, Kirabo A, Madhur MS, et al. Inflammation, immunity, and hypertensive end-organ damage. Circ Res. 2015;116(6):1022–1033. DOI:10.1161/CIRCRESAHA.116.303697
   PubMed Web of Science ®Google Scholar
• Silverstein DM. Inflammation in chronic kidney disease: role in the progression of renal and cardiovascular disease. Pediatr Nephrol. 2009;24(8):1445–1452.
   PubMed Web of Science ®Google Scholar
• Silva IVG, de Figueiredo RC, Rios DRA. Effect of different classes of antihypertensive drugs on endothelial function and inflammation. Int J Mol Sci. 2019;20(14):3458.
   PubMed Web of Science ®Google Scholar
• Lu SC, Akanji AO. Leptin, obesity, and hypertension: a review of pathogenetic mechanisms. Metab Syndr Relat Disord. 2020;18(9):399–405.
   PubMed Web of Science ®Google Scholar